Shanghai Chest Hospital Launches Multi-Center Clinical Trial to Evaluate the Success Rate of 'da Vinci' Robotic Sleeve Lobectomy After Neoadjuvant Immunotherapy
Surgical Challenges of Neoadjuvant Chemotherapy and the Role of Robotics
Recently, neoadjuvant chemoimmunotherapy, combining immune checkpoint inhibitors with chemotherapy, has become a standard treatment for non-small cell lung cancer (NSCLC) due to its ability to significantly reduce tumor size. However, this neoadjuvant therapy can cause severe fibrosis, pleural adhesion, nodal matting, and vascular inflammation in the surrounding tissues, dramatically increasing the difficulty of surgery. The clinical study led by Shanghai Chest Hospital aims to determine whether robotic-assisted thoracoscopic surgery (RATS) can overcome these physical limitations in sleeve lobectomy, which is one of the most challenging procedures. The introduction of a robotic platform with precise manipulation capabilities can reduce intraoperative bleeding and the risk of conversion to open thoracotomy, significantly improving the prognosis of high-risk patients.
Clinical Value Validation Through a Multi-Center, Prospective Design
This study is designed as a global, multi-center, prospective observational study, with participation from major medical institutions in China, France, and Italy, which significantly enhances the credibility of the data. When defining surgical failure, the clinical research team comprehensively evaluates not only the success of resection but also conversion to thoracotomy, non-R0 resection, and major postoperative complications. The study also aims to establish a technical standard for complex thoracic surgery by collecting multi-dimensional data on the surgeon's subjective assessment of surgical difficulty. Officially launched in April 2026 and currently recruiting patients, this study is expected to contribute to the development of guidelines for complex robotic surgery. Detailed data on the study design are available through the ClinicalTrials.gov APIv2 database and have been incorporated into the analysis.
Expansion of the Surgical Robotics Market and Business Opportunities
Intuitive Surgical (ISRG), the dominant leader in the surgical robotics market, aims to expand its territory into the most precise and challenging cancer surgery areas through the results of this clinical trial. Conventional video-assisted thoracoscopic surgery (VATS) has limitations in sleeve lobectomy, which involves anastomosis of blood vessels and bronchi, due to the limited degrees of freedom of its instruments. In contrast, a robotic surgical platform that provides 3D high-definition vision and anti-tremor technology has the potential to overcome these limitations and significantly improve the safety and completeness (R0) of surgery. If positive data are obtained, the adoption of robotic equipment by hospitals will accelerate, and the sales of consumables will increase, driving the medium- to long-term financial growth of robotic medical device companies.
Synergy Between Immuno-Oncology and Robotic Technology
The market for PD-1/PD-L1 immune checkpoint inhibitors, such as Keytruda (Pembrolizumab) and Opdivo (Nivolumab), developed by global pharmaceutical companies, is also expected to benefit directly and indirectly from this trial. This is because it will provide surgeons who have been hesitant to prescribe due to concerns about the safety of surgery in the neoadjuvant phase with reliable clinical evidence. Ultimately, the combination of safe robotic surgery will increase the market penetration of neoadjuvant chemoimmunotherapy and serve as a catalyst for changing the paradigm of cancer treatment. This is likely to lead to new business models, such as joint marketing or clinical collaboration between global pharmaceutical companies and surgical robot manufacturers.
This clinical trial is a prospective, multi-center study that validates the safety and complete resection rate (R0) of complex sleeve lobectomy, which has increased after the introduction of neoadjuvant immunotherapy, such as Keytruda (Pembrolizumab), in the global non-small cell lung cancer (NSCLC) market, which is worth approximately USD 30 billion. From the perspective of the surgical robotics market, dominated by Intuitive Surgical (ISRG), this trial will be an opportunity to solidify the dominant position of the da Vinci platform in the high-value thoracic surgery field and fend off competition from companies such as Medtronic (MDT). Depending on the results, a standard surgical guideline is expected to be established that can significantly reduce the conversion rate to open thoracotomy in cases of tissue hardening and adhesion, which are considered complications of neoadjuvant immunotherapy. This will clearly demonstrate the clinical utility compared to the cost of robotic equipment, leading to new equipment purchases by hospitals and increased sales of high-priced consumables, which will have short- and medium-term financial momentum. For researchers and professionals, it will present a new paradigm of cancer treatment that combines immuno-oncology and advanced robotic surgery, and promote the diversification of product portfolios.
Source: ClinicalTrials.gov (api_ct)